1958-1975 the Parkinson’s disease death rate decreased
1976-present the Parkinson’s death rate increased by 390%
WARNINGS --- LODOSYN (Carbidopa) has no antiparkinsonian effect
We are not claiming that we have published a study definitively showing carbidopa caused the 328.7% increase in the Parkinson’ death rate between 1976 and 2011. We have published a hypothesis to serve as a starting point to study this problem. Consider the following example:
89% of Parkinson’s disease patients take a combination pill containing carbidopa. This approach does not use carbidopa.
The Bottom Line:
• Carbidopa depletes vitamin B6, when on an optimal diet this represent B6 relative nutritional deficiency
• Vitamin B6 depletion causes an increased death rate
• The next question for the study is, “Does carbidopa increase the death rate?”
Figure 1 - Center for Disease Control data: Between 1958 and 1975 there was no carbidopa, only L-dopa was available. The Parkinson’s death rate dropped.
Figure 2 - Center for Disease Control Data: As published in the carbidopa B6 death paper, between 1976 (the first full year of carbidopa sales) and 2011, the Parkinson’s death rate increased by 328.7%. Currently, between 1976 and 2014 (the most recent CDC data point) the Parkinson’s death rate has increased by 390%.
The first step in solving a problem is defining what the problem might be.
A hypothesis is a starting point for scientific studies. The carbidopa B6 death paper documents the purposed hypothesis, it reads:
- The hypothesis: “Systemic vitamin B6 concentrations inversely correlate with mortality induced by coronary artery disease, colorectal cancer, stroke, heart failure, and atherosclerosis. We hypothesize that if carbidopa and benserazide significantly deplete PLP (vitamin B6), then an increased death rate will be observed.”
- The paragraph goes on to note: “During the first 15 years of prescribing L-dopa (1960–1975) it was administered without carbidopa, a practice that was associated with a decreasing death rate. On May 9, 1975, the US FDA approved carbidopa for concomitant administration with L-dopa. Between 1976 and 2011, there has been an increase in the general Parkinson’s disease death rate.”